Description
Deticene emerges as a formidable non-cell cycle specific antineoplastic agent, representing a beacon of hope in the realm of cancer therapeutics. Although the precise mechanism of its cytotoxic effects remains a subject of ongoing investigation, three plausible mechanisms have been postulated:
| Mechanism | Description |
|---|---|
| Inhibition of DNA synthesis as a purine analog | Acts as a purine analog, hindering DNA synthesis |
| Alkylating agent | Functions as an alkylating agent, impacting cellular function |
| Interaction with sulfhydryl groups | Inhibits bacterial cell growth by interacting with sulfhydryl groups |
Deticene Active Ingredient
At the heart of Deticene lies the active ingredient dacarbazine, a synthetic analog of the naturally occurring purine precursor 5-amino-1H-imidazole-4-carboxamide (AIC).
Pharmacokinetics
Upon intravenous administration, dacarbazine demonstrates a volume of distribution that surpasses total body water content, hinting at potential localization within specific body tissues, most likely the liver. Its departure from the plasma occurs in two phases, with an initial half-life of 19 minutes and a terminal half-life of 5 hours. In patients grappling with renal and hepatic dysfunctions, these half-lives extend to 55 minutes and 7.2 hours, respectively. Notably, approximately 40% of the injected dose is excreted unchanged in the urine within 6 hours, primarily through renal tubular secretion rather than glomerular filtration. Importantly, at therapeutic concentrations, dacarbazine exhibits minimal binding to human plasma proteins.
Uses
Deticene assumes a pivotal role in the therapeutic landscape, primarily serving as a treatment modality for metastatic malignant melanoma. Furthermore, it offers a ray of hope for individuals battling Hodgkin’s disease, particularly when integrated as a second-line therapy in conjunction with other efficacious agents. The extensive reach of Deticene extends to various other conditions, including:
- Advanced Soft Tissue Sarcoma
- Lymphoma
- Hodgkins
- Pheochromocytomas
- Advanced Medullary thyroid cancer
- Advanced Pancreatic neuroendocrine tumor
Dosage
The recommended dosages for Deticene hinge on the specific condition being addressed:
- Malignant Melanoma: A dosage of 2 to 4.5 mg/kg/day for 10 days is typically advised, with the option of repeating treatment at 4-week intervals. Alternatively, an alternate recommended dosage of 250 mg/m²/day IV for 5 days, with the possibility of repeating treatment every 3 weeks.
- Hodgkin’s Disease: In the context of Hodgkin’s disease, a recommended dosage of 150 mg is typically employed.
Benefits
Deticene emerges as a therapeutic powerhouse, offering multifaceted benefits across a spectrum of conditions. Its primary role in the treatment of metastatic malignant melanoma signifies a beacon of hope for patients. Furthermore, its contribution to Hodgkin’s disease management as a second-line therapy, when paired with other effective agents, underscores its versatility. The far-reaching scope of Deticene extends its healing touch to a diverse array of medical conditions, offering renewed hope and respite.
Usage
Deticene is administered intravenously, with the dosage and treatment schedule tailored to the specific ailment under consideration, as well as the overall health status of the patient.
Manufacturer
Deticene bears the hallmark of quality, being manufactured by Sanofi-aventis, a renowned name in the pharmaceutical industry.
Onset of Action
It is crucial to recognize that the onset of action for Deticene is contingent upon the condition being treated. Unlike antibiotics or pain relievers, antineoplastic agents like Deticene do not exert an immediate effect. Instead, their therapeutic benefits manifest over extended periods, underscoring the importance of patience and adherence to treatment protocols.
Aneta Parcheva –
Hello, do you have this medicine in stock?
Can I order to Bulgaria?
Thank you very much !
Medical Guidance Center –
Dear Aneta, this is Wikikenko,
At Wikikenko, we do not directly sell or ship products. Our goal is to facilitate access to information that helps guide healthcare decisions. To best assist you in sourcing the medication you need, I kindly request you fill out our “Urgent Quotation” form providing the name of the product and your location in Bulgaria. This will allow our representatives to investigate supply and delivery options with relevant distributors. Please don’t hesitate to contact me if you have any other questions in the meantime. We aim to make the procurement process as simple as possible.